Robenacoxib (Onsior) for Pain in Cats and Dogs: COX-2 Selectivity and Clinical Evidence

Bottom line.

• Robenacoxib (Onsior) is a COX-2-selective NSAID with preferential distribution to inflamed tissue, approved in the EU and available in the US for acute pain and inflammation management in cats and dogs.^1
• A randomized, blinded pilot RCT in 109 cats with degenerative joint disease-associated pain found robenacoxib treatment significantly reduced owner-assessed disability (49% reduction; p=0.01) and improved temperament and happiness at 6 weeks compared to placebo.^2
• Activity monitoring data from the same RCT showed a statistically significant increase in the 80th percentile of activity in robenacoxib-treated cats at 3 weeks (p=0.046) and 6 weeks (p=0.026).^2
• In a non-inferiority trial comparing robenacoxib to grapiprant for feline elective ovariohysterectomy, robenacoxib demonstrated comparable post-operative analgesia, supporting its role as a perioperative NSAID option in cats.^3
• The tissue-selective distribution of robenacoxib - preferential uptake at sites of inflammation with lower systemic plasma levels - is proposed to reduce gastrointestinal adverse events compared to non-selective NSAIDs, though head-to-head safety data in cats remain limited.^1

Drug facts

• Class: COX-2-selective NSAID (coxib class); phenylacetic acid derivative
• Mechanism: Preferential inhibition of cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis at inflammatory sites; tissue-selective distribution limits exposure of gastric mucosa and renal medulla relative to inflamed tissue
• Route/interval: Oral tablets (cats and dogs) and injectable formulation; indication and approved duration vary by market and species - consult current labeling
• Indication: Short-term (up to 3 days in cats per EMA label) treatment of acute pain and inflammation associated with musculoskeletal disorders and surgery; chronic DJD pain use in cats supported by pilot evidence but not universally labeled
• Approval: EMA-approved (Onsior); available in the US under Elanco (use and label duration differ by species/market - confirm current FDA status)
• Label contraindications: Dehydration, hypovolemia, renal/hepatic impairment; concurrent NSAID or corticosteroid use; hypersensitivity to the drug or class
• Label common AEs: Vomiting and soft feces most commonly reported; renal and hepatic changes at high doses in safety studies

A specific patient on robenacoxib (Onsior)?

Get an instant cited answer - no signup needed for your first question. Voyage Clinical Desk brings species-specific dose math, monitoring plans, and peer-reviewed evidence to the case in front of you.

Try Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=robenacoxib-cats-dogs-pain

What the evidence shows

Chronic pain in cats: the pilot RCT

Adrian et al. (2021; PMID 33833276) conducted the most comprehensive published RCT of robenacoxib for chronic degenerative joint disease-associated (DJD) pain in cats. The study enrolled 109 cats with DJD-pain in a parallel-group, randomized, blinded, placebo-controlled crossover design. Cats received placebo-placebo (PP), robenacoxib-robenacoxib (RR), or robenacoxib-placebo (RP) over two consecutive 3-week treatment periods. Key findings:

• Robenacoxib significantly reduced owner-assessed disability (p=0.01; 49% reduction; effect size approximately 0.3) at 6 weeks
• Robenacoxib significantly improved owner-assessed temperament (p=0.0039) and happiness (p=0.021) at 6 weeks
• For the 80th percentile of activity, more robenacoxib-treated cats showed a greater than 10% increase in activity at 3 weeks (p=0.046) and 6 weeks (p=0.026)
• Number needed to treat at 6 weeks: approximately 3.8
• Adverse effect frequencies were similar across placebo and robenacoxib groups

The authors noted high within-cat and between-cat variability in actimetry data; 82.4% of accelerometer values were zero. This study serves as proof-of-concept for robenacoxib efficacy in feline DJD pain and identified endpoints for future confirmatory studies. Note: the study was funded by Elanco Animal Health (robenacoxib developer).

Perioperative use in cats: comparison with grapiprant

Pisack et al. (2024; PMID 38511293) conducted a prospective, randomized, masked, non-inferiority clinical trial comparing grapiprant to robenacoxib for analgesia in cats undergoing elective ovariohysterectomy. The primary objective was to determine whether grapiprant was non-inferior to robenacoxib for post-operative pain control in cats. The study found that grapiprant was non-inferior to robenacoxib on the primary pain scoring endpoints, indicating both drugs provided comparable perioperative analgesia in this elective surgical model. The trial also provided comparative safety data, with no significant difference in adverse event rates between groups.

This comparison is clinically relevant because grapiprant targets the EP4 receptor downstream of COX-2, meaning alternatives exist for cats with COX-NSAID contraindications. The non-inferiority design means robenacoxib remains the reference standard against which alternatives are benchmarked in this population.

Tissue-selectivity mechanism and clinical implications

The proposed pharmacokinetic advantage of robenacoxib is its preferential distribution to inflamed tissues, where COX-2 is upregulated, while plasma (and thus systemic) concentrations decline rapidly after dosing. In vitro and pharmacokinetic studies in cats and dogs have shown that robenacoxib concentrations in inflammatory exudate remain elevated for longer than in plasma after oral or subcutaneous dosing. This property is hypothesized to maintain analgesic efficacy at the target site while minimizing systemic exposure that correlates with gastrointestinal and renal adverse effects. However, direct head-to-head clinical safety comparisons against other NSAIDs in cats with chronic disease are limited.

How this fits clinical practice

Robenacoxib occupies a practical perioperative and acute musculoskeletal pain role in cats, a species where NSAID use carries heightened renal risk and where label durations are shorter than in dogs in most markets. The DJD pilot RCT data of Adrian et al. are the most rigorous published chronic-use evidence available in cats, though the authors themselves describe it as a pilot study and the evidence for extended chronic use awaits confirmatory trials.

For dogs, robenacoxib is approved for short-term postoperative use in most markets. Clinicians should consult current label approvals and durations for each species and jurisdiction, as labeling differs between the EMA and other markets. Pre-treatment renal and hepatic baseline assessment remains standard practice before initiating chronic NSAID therapy in cats.

NSAID washout periods before switching to other NSAIDs or corticosteroids are required. Voyage Clinical Desk can provide current labeled duration guidance and monitoring reminders by species.

Voyage Clinical Desk

From clinical question to SOAP draft - cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=robenacoxib-cats-dogs-pain

References

1. Elanco/Novartis Animal Health. Onsior (robenacoxib) prescribing information. EMA EPAR product information. https://www.ema.europa.eu/en/medicines/veterinary/EPAR/onsior
2. Adrian D, King JN, Parrish RS, et al. Robenacoxib shows efficacy for the treatment of chronic degenerative joint disease-associated pain in cats: a randomized and blinded pilot clinical trial. Sci Rep. 2021;11(1):7721. https://pubmed.ncbi.nlm.nih.gov/33833276/
3. Pisack EK, Kleine SA, Hampton CE, et al. Evaluation of the analgesic efficacy of grapiprant compared with robenacoxib in cats undergoing elective ovariohysterectomy in a prospective, randomized, masked, non-inferiority clinical trial. J Feline Med Surg. 2024;26(3):1098612X241230941. https://pubmed.ncbi.nlm.nih.gov/38511293/

Changelog

• 2026-06-09: First published.

Related reads

• Grapiprant (Galliprant) for Canine Osteoarthritis Pain: EP4 Antagonism and Clinical Evidence
• Maropitant (Cerenia) for Vomiting in Dogs and Cats: Clinical Evidence